Cardea Bio
San Diego
About Cardea Bio
Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors. Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. With Cardean transistors, the company and its Innovation Partners can generate streaming multi-omics data to measure real-time biological signals. Cardea is now manufacturing chips at scale and partners have started to significantly expand the amount, type, and quality of biological data they capture by building products that Conduct Biolog.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $24.0M
- Funding stage: M&A
- Last round: Grant (May 2022)
- Website: cardeabio.com
- Phone: (+1) 619 762 1142
Industries & Categories
Biotechnology, Information Technology, Manufacturing, Semiconductor
Social Profiles
Canonical: https://fsome.com/organization/cardea-bio-60963 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.